Simulations Plus Adds to Portfolio with Release of MembranePlus

First Release of New Product in 10 Years; Provides Unique In Vitro Permeability Capabilities and Creates Cross-Selling Opportunities

LANCASTER, Calif.--()--Simulations Plus, Inc. (NASDAQ: SLP), a leading provider of consulting services and software for pharmaceutical discovery and development, today announced that it has expanded its product portfolio with the release of version 1.0 of its MembranePlus™ simulation software.

Mr. John DiBella, vice president for marketing and sales of Simulations Plus, said, “Simulations Plus continues to expand its product line with frequent release enhancements of our existing line of software products, and now the release of MembranePlus 1.0, our first completely new software product since DDDPlus™ was released about 10 years ago. This new software program is expected to appeal to a wide audience of pharmaceutical companies who use in vitro measurements of molecule permeabilities to estimate the likely permeability in preclinical species as well as humans.”

James Mullin, product manager for MembranePlus and member of the simulation technologies team in Simulations Plus, added, “Thanks to our associates from Absorption Systems, LLC, in Exton, PA, we were provided with the detailed experimental data from permeability measurements for more than 40 drugs in Caco-2 cell experiments, which enabled us to calibrate and validate the simulation model in MembranePlus. We believe MembranePlus is a unique, science-based simulation that will provide valuable insight into the results of in vitro permeability experiments to guide researchers to better project decisions.”

Dr. Viera Lukacova, team leader for simulation technologies in Simulations Plus, said: “The pharmaceutical industry uses a limited variety of laboratory experiments using cell cultures and artificial membranes to try to determine how well new molecules will be absorbed into cells in the gastrointestinal tract of animals and humans. Unfortunately, the results of such experiments for the same molecules can vary widely across different laboratories. These differences are entirely caused by changes in experimental setups, but have not been easily understood because of the number of factors involved and the complexity of the interactions among them. By developing MembranePlus, we can provide a cellular simulation model to account for how measured permeabilities are affected by a variety of factors in the experimental conditions and how to interpret the results of experiments from different laboratories. In addition, MembranePlus will provide a tool to interpret in vitro data for substrates of cell membrane transporters and to derive appropriate inputs for binding affinity constants to be used in the GastroPlus™ in vivo simulations.”

About Simulations Plus, Inc.

Simulations Plus, Inc., is a premier developer of groundbreaking drug discovery and development simulation and modeling software, which is licensed to and used in the conduct of drug research by major pharmaceutical, biotechnology, agrochemical, and food industry companies worldwide. Simulations Plus also recently acquired Cognigen, Inc. of Buffalo, NY, adding top-quality clinical trial data analysis to our offerings, as well as more than doubling our staff from 30 to 65, adding nearly 50% to revenues, and increasing earnings in the coming fiscal year that began September 1. We also provide a productivity tool called Abbreviate! for PCs. Simulations Plus, Inc., is headquartered in Southern California and trades on the NASDAQ Capital Market under the symbol “SLP.” For more information, visit our Web site at www.simulations-plus.com.

Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995 – With the exception of historical information, the matters discussed in this press release are forward-looking statements that involve a number of risks and uncertainties. Words like “believe,” “expect” and “anticipate” mean that these are our best estimates as of this writing, but that there can be no assurances that expected or anticipated results or events will actually take place, so our actual future results could differ significantly from those statements. Factors that could cause or contribute to such differences include, but are not limited to: our ability to maintain our competitive advantages, the general economics of the pharmaceutical industry, our ability to finance growth, our ability to continue to attract and retain highly qualified technical staff, our ability to identify and close acquisitions on terms favorable to the Company, and a sustainable market. Further information on our risk factors is contained in our quarterly and annual reports as filed with the U.S. Securities and Exchange Commission.

Contacts

Simulations Plus Investor Relations
Ms. Renee Bouche, 661-723-7723
renee@simulations-plus.com
or
Hayden IR
Mr. Cameron Donahue, 651-653-1854
cameron@haydenir.com

Release Summary

Simulations Plus adds to its software portfolio with the release of Membrane Plus, a new program designed to provide researchers valuable insight into the results of in vitro permeability experiments.

Contacts

Simulations Plus Investor Relations
Ms. Renee Bouche, 661-723-7723
renee@simulations-plus.com
or
Hayden IR
Mr. Cameron Donahue, 651-653-1854
cameron@haydenir.com